DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
FOSDAGROCORAT
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Glucocorticoid receptor modulator
FOSDAGROCORAT
×
Maximum Phase:
2
First Approval:
None
UNII:
HPI19004QS
Molecule Type:
Small molecule
Molecular Formula:
C29H30F3N2O5P
Molecular Weight:
574.54
AlogP:
6.28
PSA:
108.75
HBD:
3.0
HBA:
#RotB:
6.0
Source:
NCX 1000
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Portal
Unknown
NCX 1000
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C38H55NO10
Molecular Weight:
685.86
AlogP:
6.55
PSA:
154.66
HBD:
2.0
HBA:
#RotB:
14.0
Source:
DEPATUXIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Adenocarcinoma
Epidermal growth factor receptor erbB1 inhibitor
DEPATUXIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W984C353CG
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BRIVOLIGIDE
2
Unknown
Investigational
Unknown
Unknown
Pain
Unknown
BRIVOLIGIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
O32A9ET2M7
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LADARIXIN
2
Small molecule
Investigational
Unknown
Unknown
Pemphigoid, Bullous; Diabetes Mellitus, Type 1
Interleukin-8 receptor A modulator
LADARIXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DEH7Q6472O
Molecule Type:
Small molecule
Molecular Formula:
C11H12F3NO6S2
Molecular Weight:
375.35
AlogP:
1.09
PSA:
106.61
HBD:
1.0
HBA:
#RotB:
5.0
Source:
GSK239512
2
Small molecule
Investigational
Unknown
Unknown
Dementia; Multiple Sclerosis; Alzheimer Disease; Multiple Sclerosis, Relapsing-Remitting; Schizophrenia
Histamine H3 receptor antagonist
GSK239512
×
Maximum Phase:
2
First Approval:
None
UNII:
4I7U5C459M
Molecule Type:
Small molecule
Molecular Formula:
C23H27N3O2
Molecular Weight:
377.49
AlogP:
3.95
PSA:
45.67
HBD:
0.0
HBA:
#RotB:
4.0
Source:
CERDULATINIB
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Enteropathy-Associated T-Cell Lymphoma; Vitiligo
Tyrosine-protein kinase JAK1 inhibitor
CERDULATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
D1LXQ45S1O
Molecule Type:
Small molecule
Molecular Formula:
C20H27N7O3S
Molecular Weight:
445.55
AlogP:
1.37
PSA:
133.55
HBD:
3.0
HBA:
#RotB:
8.0
Source:
IPL-344
2
Unknown
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis
Unknown
IPL-344
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AFN-1252
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Enoyl-[acyl-carrier-protein] reductase [NADH] inhibitor
AFN-1252
×
Maximum Phase:
2
First Approval:
None
UNII:
T3O718IKKM
Molecule Type:
Small molecule
Molecular Formula:
C22H21N3O3
Molecular Weight:
375.43
AlogP:
3.69
PSA:
75.44
HBD:
1.0
HBA:
#RotB:
4.0
Source:
TXA127
2
Protein
Investigational
Unknown
Unknown
Obesity; Peripheral Arterial Disease; HIV Infections; Hypertension; Myelodysplastic Syndromes; Neoplasms; Respiratory Insufficiency; Severe Acute Respiratory Syndrome
Proto-oncogene Mas agonist
TXA127
×
Maximum Phase:
2
First Approval:
None
UNII:
IJ3FUK8MOF
Molecule Type:
Protein
Molecular Formula:
C41H62N12O11
Molecular Weight:
899.02
AlogP:
-1.83
PSA:
377.24
HBD:
13.0
HBA:
#RotB:
25.0
Source:
SCYLLITOL
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Bipolar Disorder; Down Syndrome
Unknown
SCYLLITOL
×
Maximum Phase:
2
First Approval:
None
UNII:
1VS4X81277
Molecule Type:
Small molecule
Molecular Formula:
C6H12O6
Molecular Weight:
180.16
AlogP:
-3.83
PSA:
121.38
HBD:
6.0
HBA:
#RotB:
0.0
Source:
TENOFOVIR EXALIDEX
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Communicable Diseases
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
TENOFOVIR EXALIDEX
×
Maximum Phase:
2
First Approval:
None
UNII:
K7J545MEMA
Molecule Type:
Small molecule
Molecular Formula:
C28H52N5O5P
Molecular Weight:
569.73
AlogP:
6.86
PSA:
134.61
HBD:
2.0
HBA:
#RotB:
25.0
Source:
ARRY-502
2
Small molecule
Investigational
Unknown
Unknown
Asthma
G protein-coupled receptor 44 antagonist
ARRY-502
×
Maximum Phase:
2
First Approval:
None
UNII:
5LO1ZK1LCW
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
C-1311
2
Small molecule
Investigational
Unknown
Unknown
Unknown
DNA topoisomerase II inhibitor
C-1311
×
Maximum Phase:
2
First Approval:
None
UNII:
MZ4Y5H4OAB
Molecule Type:
Small molecule
Molecular Formula:
C20H22N4O2
Molecular Weight:
350.42
AlogP:
2.9
PSA:
69.87
HBD:
2.0
HBA:
#RotB:
6.0
Source:
MIRAMISTIN ION
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MIRAMISTIN ION
×
Maximum Phase:
2
First Approval:
None
UNII:
62S6VPY15U
Molecule Type:
Small molecule
Molecular Formula:
C26H47N2O+
Molecular Weight:
403.68
AlogP:
6.47
PSA:
29.1
HBD:
1.0
HBA:
#RotB:
18.0
Source:
NBTXR3
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
NBTXR3
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATEVIRDINE MESYLATE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
ATEVIRDINE MESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
N24015WC6D
Molecule Type:
Small molecule
Molecular Formula:
C21H25N5O2
Molecular Weight:
379.46
AlogP:
2.97
PSA:
73.49
HBD:
2.0
HBA:
#RotB:
5.0
Source:
PF-05212377
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Serotonin 6 (5-HT6) receptor antagonist
PF-05212377
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRADIGASTAT SODIUM
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
PRADIGASTAT SODIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
X0EWE8TT2H
Molecule Type:
Small molecule
Molecular Formula:
C25H23F3N3NaO2
Molecular Weight:
477.46
AlogP:
6.65
PSA:
75.11
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ARASERTACONAZOLE
2
Small molecule
Investigational
Unknown
Unknown
Candidiasis, Vulvovaginal
Unknown
ARASERTACONAZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
PR82C5R514
Molecule Type:
Small molecule
Molecular Formula:
C20H15Cl3N2OS
Molecular Weight:
437.78
AlogP:
7.02
PSA:
27.05
HBD:
0.0
HBA:
#RotB:
6.0
Source:
1018 ISS
2
Unknown
Investigational
Unknown
Unknown
Colorectal Neoplasms; HIV Infections; Hepatitis B, Chronic; Lymphoma, Non-Hodgkin; Severe Acute Respiratory Syndrome
Toll-like receptor 9 agonist
1018 ISS
×
Maximum Phase:
2
First Approval:
None
UNII:
25DT549L0G
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TAURODEOXYCHOLIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Sepsis; Dermatitis, Atopic
Unknown
TAURODEOXYCHOLIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
20668G0RPI
Molecule Type:
Small molecule
Molecular Formula:
C26H45NO6S
Molecular Weight:
499.71
AlogP:
3.4
PSA:
123.93
HBD:
4.0
HBA:
#RotB:
7.0
Source:
PULRODEMSTAT BESILATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia; Lymphoma, Non-Hodgkin; Prostatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms
Unknown
PULRODEMSTAT BESILATE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C30H29F2N5O5S
Molecular Weight:
609.66
AlogP:
3.2
PSA:
97.17
HBD:
1.0
HBA:
#RotB:
4.0
Source:
IMR-687
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
IMR-687
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SETOGEPRAM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SETOGEPRAM
×
Maximum Phase:
2
First Approval:
None
UNII:
879OVM0Y1S
Molecule Type:
Small molecule
Molecular Formula:
C13H18O2
Molecular Weight:
206.28
AlogP:
3.05
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
6.0
Source:
TOPIROXOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Hyperuricemia
Xanthine dehydrogenase inhibitor
TOPIROXOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
0J877412JV
Molecule Type:
Small molecule
Molecular Formula:
C13H8N6
Molecular Weight:
248.25
AlogP:
1.8
PSA:
91.14
HBD:
1.0
HBA:
#RotB:
2.0
Source:
POL6326
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
POL6326
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
P276-00
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
P276-00
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAPADENOSON
2
Small molecule
Investigational
Unknown
Unknown
Angina, Stable; Atrial Fibrillation
Adenosine A1 receptor partial agonist
CAPADENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
O519NVW73R
Molecule Type:
Small molecule
Molecular Formula:
C25H18ClN5O2S2
Molecular Weight:
520.04
AlogP:
5.51
PSA:
128.84
HBD:
2.0
HBA:
#RotB:
8.0
Source:
QUETMOLIMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Crohn Disease; Liver Cirrhosis, Biliary
Fractalkine inhibitor
QUETMOLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
G8NT4Q571B
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BLX-028914
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BLX-028914
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
X
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
X
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IBOCTADEKIN
2
Protein
Investigational
Unknown
Unknown
Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Melanoma
Unknown
IBOCTADEKIN
×
Maximum Phase:
2
First Approval:
None
UNII:
X08H9UZ7TO
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CC-11050
2
Small molecule
Investigational
Unknown
Unknown
Lupus Erythematosus, Cutaneous; Tuberculosis
Phosphodiesterase 4 inhibitor
CC-11050
×
Maximum Phase:
2
First Approval:
None
UNII:
1Z08G7438A
Molecule Type:
Small molecule
Molecular Formula:
C24H28N2O6S
Molecular Weight:
472.56
AlogP:
3.18
PSA:
102.01
HBD:
1.0
HBA:
#RotB:
9.0
Source:
AZD1305
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation; Atrial Flutter
HERG blocker
AZD1305
×
Maximum Phase:
2
First Approval:
None
UNII:
CZO834LXQM
Molecule Type:
Small molecule
Molecular Formula:
C22H31FN4O4
Molecular Weight:
434.51
AlogP:
1.99
PSA:
87.06
HBD:
1.0
HBA:
#RotB:
7.0
Source:
1
2
…
131
132
133
134
135
136
137
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA